Thank you for the great response to our presentation at #ESGCT2024 in Rome! 💫 We're excited by the engaging discussion following our CTO's presentation at #ESGCT2024 in Rome. The dynamic Q&A session demonstrated the scientific community's deep interest in advancing non-viral approaches to CAR-T cell therapy. Our presentation on targeted lipid nanoparticle (tLNP) technology sparked valuable discussions around key aspects of in vivo CAR-T cell generation, including biodistribution, integration analysis, and targeting effectiveness. Our preclinical data showed: • Successful generation of persistent CAR-T cells in vivo • Effective tumor control in human PBMC-engrafted mouse models of B-cell leukemia • Extended survival in human PBMC-engrafted mouse models of B-cell leukemia We appreciate the thoughtful questions and technical discussions that followed our presentation. Stay connected as we continue our work in revolutionizing cell therapy accessibility. Thank you Jacek Lubelski and Team! #CellTherapy #GeneTherapy #Biotechnology #Innovation #CART #NanoEngine #NanoCelltx #Nonviral
A packed room during the “Non-viral vector” session at ESGCT in Rome. Jacek Lubelski of Nanocell Therapeutics illustrated theresults of the EIC Pathfinder project Nano-Engine showing targeted LNP for in vivo CAR T.
